Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 5/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 4/20 | 0.39 |
| ▸ | DRD3 | P35462 | 2/20 | 0.39 |
| ▸ | DRD1 | P21728 | 1/20 | 0.39 |
| ▸ | DRD4 | P21917 | 1/20 | 0.39 |
| ▸ | DRD5 | P21918 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.38 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.37 |
| ▸ | KMO | O15229 | 1/20 | 0.37 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5958348 | 0.90 | KMO (0.49) | DRD2TSHRDRD3DRD1DRD4 | |
| SCHEMBL23662671 | 0.81 | PRMT5 (0.39) | DRD2TSHRDRD3DRD1DRD4 | |
| SCHEMBL29866165 | 0.81 | PRMT5 (0.39) | DRD2TSHRDRD3DRD1DRD4 | |
| SCHEMBL18640667 | 0.79 | DRD2 (0.41) | DRD2TSHRHTR2CDRD3DRD1 | |
| SCHEMBL16957589 | 0.79 | DRD2 (0.55) | DRD2TSHRHTR2CDRD3DRD1 | |
| SCHEMBL22805478 | 0.79 | SIGMAR1 (0.47) | DRD2HTR2CDRD3DRD1DRD4 | |
| SCHEMBL2918150 | 0.79 | DRD2 (0.41) | DRD2HTR2CDRD3DRD1DRD4 | |
| SCHEMBL17986245 | 0.79 | HDAC4 (0.42) | DRD2HTR2CDRD3DRD1DRD4 | |
| SCHEMBL3176710 | 0.79 | PNMT (0.47) | DRD2 | |
| SCHEMBL30125100 | 0.79 | DRD2 (0.41) | DRD2TSHRHTR2CDRD3DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1989194-B1 | CYCLIC SULFONES USEFUL AS BACE INHIBITORS | NOVARTIS AG (CH) | 2010-08-25 | — | — | EP | disclosed |
| US-20090099207-A1 | Cyclic sulfones useful as BACE inhibitors | RUEEGER HEINRICH | 2009-04-16 | — | — | US | disclosed |
| CN-101384580-A | Cyclic sulfones useful as BACE inhibitors | NOVARTIS AG (CH) | 2009-03-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099207-A1 | Cyclic sulfones useful as BACE inhibitors | BACE1, BACE2, APP | DRD2 4134/4885TSHR 4711/4885HTR2C 4178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.